JM Financial has retained its Buy rating on Metropolis Healthcare with a target price of Rs 734, implying 27.2% upside. The brokerage calls it the cheapest among India’s leading listed diagnostic players, citing attractive valuations, network expansion, stronger B2C growth and improving margins as key drivers.
JM Financial has retained its Buy rating on Metropolis Healthcare with a target price of Rs 734, implying 27.2% upside. The brokerage calls it the cheapest among India’s leading listed diagnostic players, citing attractive valuations, network expansion, stronger B2C growth and improving margins as key drivers.
<iframe src="https://hindustansphere.com/embed/cluster/f0f1f3d9774730aee3796a3effa7b5eea3f35096" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="JM Financial calls Metropolis Healthcare ‘best-value diagnostic stock’, sees up to 27% upside"></iframe>
